Michael Pourdehnad
Hematology Oncology | Hematology
400 Parnassus Ave.
Fourth Floor
San Francisco, CA 94143
Fourth Floor
San Francisco, CA 94143
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Corrigendum to "Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer": [Ann Oncol 36 (2025) 76-88].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 08, 2026
Corrigendum to "Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer": [Ann Oncol 36 (2025) 76-88].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 08, 2026
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 29, 2024
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
Journal: The New England journal of medicine
Published: August 30, 2023
Model based assessment of food and acid reducing agent effects on oral absorption of mezigdomide (CC-92480), a novel cereblon E3 ligase modulator.
Journal: CPT: pharmacometrics & systems pharmacology
Published: March 02, 2023
Correction to: Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies.
Journal: The AAPS journal
Published: January 17, 2022
Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
Journal: EJHaem
Published: November 08, 2021
Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma.
Journal: EJHaem
Published: November 05, 2021
Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies.
Journal: The AAPS journal
Published: April 15, 2021
Population Pharmacokinetics of CC-122.
Journal: Clinical pharmacology : advances and applications
Published: March 12, 2021
CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia.
Journal: Journal of medicinal chemistry
Published: February 16, 2021
Last Updated: 09/26/2026